brent saunders
TRANSCRIPT
Eye Disease Remains a Significant and Growing Problem
Glaucoma is the second leading cause of blindness globally, according to WHO. Affecting 80 million by 2020.
Persistence rates are generally under 50% as early as the first year of treatment
As many as 80% of patients fail to use their drops regularly~3
Sources: Varma et al. Am J Ophthalmol 2012. CDC Statistics 2010 & 1995. WHO Statistics 2013 & 2015. Cowen and Company Ophthalmology 2015. Evaluate Pharma Glaucoma Report: published Aug 2015Source: 2007 DEWS guidelines. CDC 2014. NEI 2010.
Glaucoma
Dry eye is one the most prevalent ophthalmology disease in the general population with an estimated 15-18%
Dry eye is estimated to affect approximately 30 million patients in the U.S. There are two types of Dry Eye: aqueous-deficient and evaporative 30
million patients
in the US
Dry Eye
13.13.13 2.48 2.15 0.31 0.135
DiabeticNeuropathies
Wet AMD Dry AMD Retinal VeinOcclusion
OpticNeuritis
RetinitisPigmentosa
21million
patients in the US
US Prevalence (Millions)Retinal Disease
million patients
in the US
$684 $1,280$340$517
$2,422
$2,405$617
$652$673
$1,373$716
$868$1,494
$3,736
0
3,000
6,000
9,000
12,000
2010 2014
US
Eye
Car
e S
ales
($
Mill
ion)
Dry Eye Artificial Tears
Source: IMS Health Eye Care Market Report 2009-2015; Team Thinking; GBI Ophthalmology Tx in Major Developed Markets to 2019 (2013); 2016 Retina Growth Plan
Eye Care Market Poised for Growth
▲ The number of treated patients is expected to increase due to an aging population and the expansion of access to health care.
▲ Dry Eye market expansion with more therapeutic options
▲ Advances in drug delivery and devices address key barriers and re-ignite growth in glaucoma.
▲ Market expansion opportunities with new products in underserved diseases – e.g., presbyopia, blepharitis, viral conjunctivitis, MGD
▲ Growth in surgical market will increase utilization of anti-inflammatories.
▼ Generic alternatives and cost-control measures
MGD = Meibomian Gland Dysfunction
CAGR (%)
0%
11%
17%
1.4%
20%
4.9%
26%
Future US Market GrowthDrivers and Barriers
US Eye Care Market Growth by Therapeutic Area
SOURCE: Thomson Reuters, PitchBook database
A New Pharmaceutical Innovation Ecosystem
Fueled by Significant Investments
0
500
1,000
1,500
2,000
2,500
3,000
3,500
0
0.6
1.2
1.8
2.4
3.0
3.5
4.1
4.7
5.3
5.9
6.5
Ven
ture
cap
ital i
nves
ted,
$B
Num
ber
of b
iote
ch s
tart
ups
2010
2000
2005
19952014
Number of biotech startups
Venture capital invested, $B
• Continued VC funding
• Scientific creativity
• Professional management
Sustainability
Revenues of all NME-grade compounds launched in a given year cumulated for 7-8 years. Includes all innovative compounds classified as NME or BLA, excluding generics, biosimilars and NDA products (new derivatives, new formulations etc.)SOURCE: Evaluate 2014
14%Biotech & Start-up Companies
24%Regional PharmaNon-profit Academia Specialty
academia
Specialty
GLOBALPHARMA
Biotech & start-ups
Regional Pharma62%
Global Pharma
1998Source of NMEs by originator typePharma Innovation Ecosystem
Evaluate Jul 20 Revenues of all NME-grade compounds launched in a given year cumulated for 7-8 years. Includes all innovative compounds classified as NME or BLA, excluding generics, biosimilars and NDA products (new derivatives, new formulations etc.)SOURCE: Evaluate 2014 14; McKinsey analysis
academia
Specialty
GLOBALPHARMA
Biotech & start-ups
Regional Pharma
2013
50%Biotech & Start-up Companies
28%Regional PharmaNon-profit Academia Specialty
22%Global Pharma
Pharma Innovation Ecosystem
Source of NMEs by originator type
academia
GLOBALPHARMA
Biotech & start-ups
Regional Pharma
Specialty
TODAY
NEW Pharma Innovation Ecosystem
Customer
PRIVATE COMPANIES VENTURE
CAPITAL
REGIONAL PLAYERS
PRIVATE EQUITY
Start-ups
Ideas
PATIENTS
DEVELOPMENT POWERHOUSE
COMMERCIAL MACHINE
BUSINESS DEVELOPMENT
THERAPEUTIC AREA
LEADER
Customer Intimacy is Critical
We discover, acquire, partner and collaborate on compounds at all stages of R&D with a strong preference for validated targets or compounds with proof of concept.
CGRPs
Ozurdex
Latisse
Avycaz
Linzess
Kybella
XEN45
Bimatoprost SR
Restasis X
Abicipar
Relamoralin
KYTH-105
Juvederm Botox
AGN-241660
Rapastinel
SER 120
Esmya
Nebivolol
VraylarBystolic/Vals
artan
Viberzi
Dalvance
OD-01
customer
Teflaro
Combigan
CommercializationDEVELOPMENT
DISCOVERY
Allergan Model
SOURCE: Evaluate; Capital IQ1 Based on 2014 R&D spend/revenue and % of clinical non-generic NME, NDA, and biologic pipeline assets that are non-organic
Low High% pipeline externally sourced1
Low
High
R&
D /
Sal
es1
OPEN SCIENCE
LOW-COST
TRADITIONAL
Allergan is a Forerunner in
Use Open Science Model to Sustain Leadership
Underlying Logic Behind Eye Care Strategy
Leading Therapies In:
Dry Eye
Glaucoma
Retina
in Eye Care
17
Eye
Care
Tripligan (MMT) Ocular HTN & Glaucoma
FPR2Agonist Dry Eye Disease
MimetogenDry Eye
Bimatoprost SR Glaucoma
Ganfort MDPF
Restasis MDPF
Omega 3 OTC Dry Eye
Pilo/Oxy Presbyopia
Cortisol Analog Dry Eye Disease
Brimo DDS Atrophic AMD
Androgen Evaporative Dry Eye
Cyclosporine SR Dry Eye
DARPin®
DME
Dual DARPin®
AMD
DARPin® SR AMD
OCU Tearbud 1 Dry Eye
DARPin®
AMD
Allergan Committed to Eye Care Drug
Development